MiNK TherapeuticsINKT
About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Employees: 23
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.1% less ownership
Funds ownership: 2.14% [Q3] → 2.04% (-0.1%) [Q4]
11% less capital invested
Capital invested by funds: $632K [Q3] → $565K (-$67.4K) [Q4]
12% less funds holding
Funds holding: 26 [Q3] → 23 (-3) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 29 / 163 met price target | 290%upside $35 | Buy Reiterated | 18 Mar 2025 |
Financial journalist opinion
Based on 3 articles about INKT published over the past 30 days









